Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript. Sunil Kumar Gupta mentions INR194 crores still in the bank from previous fundraising efforts. No updates or discussions on new capital raising initiatives, neither equity nor debt, were provided. The focus remains on operational execution, cost optimization, and project execution like the 7ACA project. Management hasn't indicated any plans for fresh fundraising in the near term.

Any current/future capex/capital investment/strategic investment?

No changes in capex timelines; projects on track as planned (Page 17). Capex ongoing for 7ACA and Cefiderocol lines with no new expansion planned in the sterile business for the near future (Pages 10, 17). Sterile capacity expanded last year and expected to serve well for the next couple of years (Page 10). Cefiderocol project under construction; commissioning expected by November-December 2026 (Page 8). 7ACA project execution continues as planned despite delays; no material changes in PLI incentive or duration (Pages 8-9). No immediate capacity expansion required for next 2 years to

Future growth expectations in sales/revenue/volumes?

Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain. Recent quarters showed 15%-20% volume growth; however, price corrections in key products have muted topline revenue growth. The company is cautious about maintaining the same 20% year-on-year growth in FY '25 due to sharp spot price corrections, mainly in oral products. Long-term growth remains positive with sustained volume increases and operational excellence. New product launches like Enmetazobactam and Cefiderocol (commissioned by December 20

Future growth expectations in earnings/operating earnings/profits/EPS?

Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year. The company maintains a stable gross margin guidance of around 40%, plus or minus 2%. They anticipate EBITDA margin expansion of approximately 100 basis points annually due to volume growth and productivity improvements. Long-term growth expectation is a compound annual growth rate (CAGR) of about 20% over 3 years, though short-term yearly forecasts are uncertain due to market volatility and price corrections. Price volatility affects revenue but the company focuse

IN US

Sale is live|00:00:00left today

Orchid Pharma LtdQ4 FY26Pharmaceuticals & Biotechnology

Orchid Pharma Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹963P/E: 139.1Market Cap: ₹3.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

0 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Orchid Pharma projects approximately 20% volume growth annually based on the past 3 years' CAGR, though short-term quarterly forecasts are uncertain.
→Recent quarters showed 15%-20% volume growth; however, price corrections in key products have muted topline revenue growth.
→The company is cautious about maintaining the same 20% year-on-year growth in FY '25 due to sharp spot price corrections, mainly in oral products.
→Long-term growth remains positive with sustained volume increases and operational excellence.
→New product launches like Enmetazobactam and Cefiderocol (commissioned by December 2026) are expected to contribute to future growth, though Cefiderocol revenue is anticipated beyond 2 years.
→The AMS division (domestic hospital business) is investing for growth with a breakeven expected after one more year.
→Regulatory milestones, capacity expansions, and strategic partnerships will support sustained growth and value creation.

Margin guidance

Category 3

→Orchid Pharma has shown a 15% growth in total income for 9 months FY '25 and a 26% increase in PAT over the same period last year.
→The company maintains a stable gross margin guidance of around 40%, plus or minus 2%.
→They anticipate EBITDA margin expansion of approximately 100 basis points annually due to volume growth and productivity improvements.
→Long-term growth expectation is a compound annual growth rate (CAGR) of about 20% over 3 years, though short-term yearly forecasts are uncertain due to market volatility and price corrections.
→Price volatility affects revenue but the company focuses on healthy margins rather than volume at reduced prices.
→No short-term forecast is given for FY '25 full-year growth; however, the longer trend remains positive.
→AMS division expects a negative EBITDA for another year before becoming accretive.
→The company foresees no tax payments likely for the next 4 to 5 years due to carry forward losses.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned fundraising through debt or equity in the call transcript.
→Sunil Kumar Gupta mentions INR194 crores still in the bank from previous fundraising efforts.
→No updates or discussions on new capital raising initiatives, neither equity nor debt, were provided.
→The focus remains on operational execution, cost optimization, and project execution like the 7ACA project.
→Management hasn't indicated any plans for fresh fundraising in the near term.

Order book

The transcript provided does not explicitly mention current or expected order book or pending orders for Orchid Pharma Limited. Key points related to business and growth include: - The company is experiencing 15-20% volume growth year-on-year, with cumulative 9-month growth around 20%. - Price corrections in top products have impacted sales but margins remain healthy. - Focus is on long-term sustainable growth rather than short-term volume spikes. - Investments in new products like Enmetazobactam and Cefiderocol are ongoing; Cefiderocol commissioning expected in December 2026. - Continued capacity expansions in oral and sterile segments have been recently completed with no immediate further plans. - The AMS division is still in investment phase and expected to become EBITDA accretive after FY25. No direct mention of order books or pending orders was found in the available transcript extracts.

Capex plans

→No changes in capex timelines; projects on track as planned (Page 17).
→Capex ongoing for 7ACA and Cefiderocol lines with no new expansion planned in the sterile business for the near future (Pages 10, 17).
→Sterile capacity expanded last year and expected to serve well for the next couple of years (Page 10).
→Cefiderocol project under construction; commissioning expected by November-December 2026 (Page 8).
→7ACA project execution continues as planned despite delays; no material changes in PLI incentive or duration (Pages 8-9).
→No immediate capacity expansion required for next 2 years to sustain growth (Page 13).
→Strategic focus includes regulatory milestones, new product introductions, and AMS division expansion (Page 5).

How does Orchid Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Orchid Pharma Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Orchid Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio